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Outcome and reproducibility of Heart Team decisions: a single center experience
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Background: A multidisciplinary team (MDT) approach is now a class IC recom-
mendation in the European and American guidelines for decision-making in patients
with complex coronary artery disease (CAD). The Heart Team (HT) consists of at
least one interventional cardiologist, a cardiac surgeon and a non-invasive cardiolo-
gist. The aim of this study was to evaluate the implementation and consistency of HT
decisions in a tertiary cardiac centre.
Methods: We prospectively evaluated our data derived from 51 MDT meetings held
between April 2012 and April 2013. A subset of cases was randomly selected and re-
presented with the same clinical data, at least 6 months after the initial decision in
order to evaluate the consistency of initial decisions.
Results: Amongst patients discussed (n¼399) 23% were females. An average of 8
patients were discussed in each weekly meeting. This was attended by a median
number of 1 non-interventional cardiologist, 3 interventional cardiologists and 3 car-
diac surgeons. The most common HT decisions included continued medical man-
agement (30%), coronary artery bypass grafting (CABG) (26%) and percutaneous
coronary intervention (PCI) (17%). Other decisions, such as further assessment of
symptoms or evaluation with dobutamine stress echo, cardiac MRI, repeat coronary
angiogram, pressure wire studies (PWS), intravascular ultrasound (IVUS) or exercise
treadmill test (ETT) were made in 27% of the cases discussed. HT decisions were
implemented in 93% of the cases. The most common reasons for non-implementation
were unrecognised comorbidities (n¼11), change of symptoms (n¼7), patient refusal
(n¼7) and death (n¼4). On re-discussion of the same data (n¼25) within a median
period of 9 months 20% of decisions (n¼5) differed from the original HT
recommendation.
Conclusions: The Heart Team is a robust process in the management of patient with
complex CAD and decisions are largely reproducible. Although outcomes are
successfully implemented in the majority of the cases, it is important that all clinical
information is available during discussion and patients' preference is taken into
account.
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Increasing Utilization of Percutaneous Coronary Interventions from 1988 to 2006
in Patients with type 2 Diabetes Mellitus in the United State
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Background: Percutaneuse coronary interventions have increased in recent years in
high risk patients. The goal of this study was to evaluate this trend in type 2 diabetes
(DM) patients undergoing PCI in the United States.
Methods: The Nationwide Inpatient Sample (NIS) database was utilized to calculate
the age-adjusted incident rate of PCI performed in type 2 DM patient from 1988 to
2006 in the United State using ICD-9 coding for PCI and type 2 DM.
Results: A total population of 504371 type 2 DM patients underwent PCI between
1988-2006 were available for our study over the age of 40. We found that age adjusted
rate of PCI performed in type 2 DM patient gradually increased with highest rate
in 2006. Age adjusted rate for DM patients undergoing PCI was 10.1 per 100,000 in
1988 vs. 70.1 per 100.000 in 2006 (p<0.01). Non-DM patient had similar increase in
PCI over the years studied.
Conclusions: PCI performed increasingly in type 2 DM patients in last few decades.
The cause of this trend is not known but is most likely related to PCI being performed
more frequently in high risk patient or related to increasing incidence of PCI in the
popolation.JACC Vol 62/18/Suppl B j October 27–November 1, 2013 j TCT AbstrTCT-316
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Impact of Glycemic Control on Cardiovascular Outcomes in Secondary
Prevention of Diabetic Patients after a First Coronary Event. Insights from an
international registry including 1,036 patients.
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Background: The effect of glycemic control on major cardiovascular (CV) and
cerebrovascular events (MACCE) after percutaneous coronary intervention in patients
with Type 2 diabetes (DM) remains controversial.
Methods: We report an international, observational study on DM patients with
coronary artery disease eligible for percutaneous coronary intervention. Patients with
Type 1 diabetes and ST elevation myocardial infarction (MI) were not included.
Clinical follow up and glycemic control as assessed by glycosylated hemoglobin
(HbA1c) were obtained at 1 year.
Results: A total of 1,036 patients aged 61.9 (+/-0.3) years were included. CV risk
factors included smoking, hypercholesterolemia, hypertension and overweight in
49.7%, 78.2%, 76.6% and 47.6%, respectively. Clinical presentation included acute
coronary syndrome, silent ischemia and stable angina in 22%, 15.6% and 30.8%,
respectively. 1,687 coronary stenosis were treated with at least one Xience everolimus
eluting stent (EES) in the the left main (n¼52), the left anterior descending artery
(n¼744), the left circumﬂex artery (n¼506) or the right coronary artery (n¼538). The
mean length and diameter of the implanted EES were 19.0+/-0.2mm and 2.88+/-
0.01mm, respectively. MACCE was observed in 95 (9.2%) patients: CV death (n¼16
(1.5%)), myocardial infarction (n¼8 (0.8%)), ischemia driven revascularization (66
(6.4%)) and ischemic stroke (n¼5 (0.5%)). The MACCE rate was not signiﬁcantly
different among the low, intermediate and high tertile groups of HBA1c.
Conclusions: The use of EES in a large population of DM2 patients is associated with
a low MACCE rate at 1 year. No beneﬁcial effect of good glycemic control as
assessed by HBA1c on MACCE was observed in this “all-comer” diabetic population
at 1 year.
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Cardioprotection with Glucagon-like Peptide-1 (GLP-1) may occur independent
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Background: Mechanisms for cardioprotection with Glucagon-like Peptide-1 (GLP-
1) are unclear. Human studies have mainly assessed the effects of GLP-1 when
administered after an ischemic insult, when reperfusion injury pathways have been
activated. There is however, limited data investigating the impact of GLP-1 on supply
ischemia when given before PCI.
Methods: 30 patients with normal LV function were studied during elective LAD
PCI. Pressure-volume loops were recorded using a LV conductance catheter at
baseline, during 1-min low-pressure balloon occlusion (BO1), after 30mins recovery,
and during a 2nd 1-min balloon occlusion (BO2). Patients were randomized to receive
either IV saline (control) or GLP-1 (7-36; 1.2 pmol/kg/min) given before BO1.
Coronary wedge pressure (Pw) & simultaneous coronary artery/sinus glucose samples
were measured during BO1. Data were analyzed ofﬂine by a blinded reviewer for
measures of systolic (dP/dTmax) & diastolic (dP/dTmin) function.
Results: Compared with controls, pre-treatment with GLP-1 reduced LV dysfunction
during BO1 (D dP/dTmax -5.7% vs -15.3%, p¼0.04; D dP/dTmin -10.4% vs -21.8%,
p¼0.04), improved recovery at 30mins (D dP/dTmax +4.8% vs -12.2%, p¼0.03) &
reduced LV dysfunction after BO2 (D dP/dTmax -7.7% vs -25.3%, p¼0.02; D dP/
dTmin -15.3% vs -30.3%, p¼0.05). Collateral recruitment (Pw 24.4 vs 20.3mmHg,
p¼0.36; pressure-derived collateral ﬂow index 0.19 vs 0.17, p¼0.57) & glucose
utilisation was similar in both groups.acts/POSTER/Miscellaneous Coronary Topics B101
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dysfunction & stunning, independent of coronary collaterals and metabolic substrate.
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Pathological ﬁndings of basophilic foreign materials in 10 coronary artery and 3
intracerebral Pipeline cases
Kazuyuki Yahagi1, Fumiyuki Otsuka1, Kenichi Sakakura1, Elena Ladich1,
Frank D. Kolodgie1, Renu Virmani1
1CVPath Institute, Inc., Gaithersburg, MD
Background: Today percutaneous intervention is the preferred treatment for athero-
sclerotic disease in any part of the body, therefore there is a greater potential for
embolization of material used on such devices. Several reports have shown that
foreign materials such as the hydrophilic polymer can induce obstruction of small
vessels with distal necrosis as well as granulomatous hypersensitivity reaction
(Modern Pathology 2010; 23:921-30).
Methods: We reviewed autopsy registry ﬁles from 2005 to 2013 and identiﬁed 13
cases of foreign body hydrophilic polymer that was associated with untoward effects.
Results: There were 10 coronary (total stents ¼ 29) and 3 intracerebral interventions
that at autopsy had foreign materials identiﬁed around the stent strut or in the distal
bed. Overlapping stent were used in 6 cases (60%) and mean stented lesion length was
2718mm in the coronary artery cases. All showed the presence of foreign body
basophilic materials in the intramural small coronary artery with or without chronic
inﬂammation, ﬁbrin and giant cells. Foreign body basophilic materials were observed
around stent struts in 3 cases. Basophilic materials were identiﬁed in the left ventricle
in 6 cases (60%), right ventricle in 3 cases (30%) and in both ventricle in 1 case (10%).
Most of the basophilic materials were seen in the epicardial one third of the ventricle
with or without myocyte necrosis. The 3 intracerebral cases involved the internal
carotid artery in 2 and the basilar artery in 1, all had Pipeline stent implantation and in
2 cases embolic material was identiﬁed in the area of the intracerebral hemorrhage
and/or in surrounding brain sections with or without inﬂammation. All 3 Pipeline
stents in the artery showed basophilic material on histologic examination. In some
cases the basophilic material was identiﬁed to be hydrogel on spectroscopic
examination.
Conclusions: Hydrogel polymers are commonly used on interventional devises for
improvement of deliverability. However, unexpectable embolization of basophilic
hydrogel was identiﬁed in all 13 cases. Hydrogel is not a benign material and its use in
its current form on devices should be changed.
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The Paclitaxel-coated balloon catheter presents a therapeutic alternative in select
coronary indications – Results of an analysis of the raw data of 7 prospective
studies
Martin Unverdorben1, Hannah Nuiding1, Christian Vallbracht2, Bruno Scheller3,
Ralf Degenhardt1
1Clinical Research Institute, Rotenburg, Germany, 2Center for Cardiovascular
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Background: The paclitaxel-coated balloon catheter (DCB) based on the
PACCOCATH technology has yielded angiographic and clinical results superior to
drug-eluting stents in situations like bare-metal in-stent restenosis and a trend towards
better outcome in small coronary vessels and side branches of coronary bifurcations.
The sample size of each individual study, however, was relatively small
Methods: To strengthen the evidence, the raw data of all 401 patients (63.310.5
years, 74.3% men) with 446 stenoses that were treated with SeQuentTM Please DCB
or its predecessor in the PACCOCATH ISR I/II, PEPCAD I, II, IV, V and INDICOR
studies were analyzed. Main outcome parameters encompassed the 6-9month angio-
graphic and 1-year MACE data. The patients were categorized into the following
groups: De-novo lesions in native vessels treated with DCBonly (82Px./106 stenoses),
stenoses in native vessels treated with DCB and several types of bare-metal stents
(BMS) (DCB+BMS: 202Px. /223 stenoses) and bare-metal in-stent restenosis treated
with DCB only (BMS-ISR; 117Px./117 stenoses).
Results: DCBonly compared to BMS-ISR did not show statistically different results
for late lumen loss (LLL) (0.190.59mm vs 0.230.53mm), LLLIndex (0.150.31B102 JACC Vol 62/18/Suppl B j October 27–Novemvs 0.160.56), target lesion revascularization (TLR) (4/82 (4.9%) vs 6/117 (5.1%)),
lesion related myocardial infarction major and target lesion thrombosis (both
parameters in both groups 0), cardiac death (0/82 (0%) vs 1/117 (0.9%)), and major
adverse cardiac events (MACE) (4/82 (4.9%) vs 6/117 (5.1%)). In DCB combined
with BMS, TLR (16/202 (7.9%)), lesion related myocardial infarction (7/202 (3.5%)),
target lesion related thrombosis (5/202 (2.5%)), and cardiac death (3/202 (1.5%)) were
statistically not different compared to DCB only in de-novo lesions while in
DCB+BMS the LLL (0.550.65mm) was signiﬁcantly (p<0.001) greater as were
LLLIndex (0.340.41, p<0.001) and MACE 25/202 (12.4%) (p¼0.08). The 1-year
MACE rates were independent from gender, and the cardiovascular risk factors
smoking, hyperlipidemia, obesity, hypertension, and diabetes.
Conclusions: Angiographically, DCBonly was superior to its combination with bare
metal stents whereas MACE data trended superior.
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Impact of Diabetes Duration on Long-term Clinical Outcomes following
Coronary Revascularization: A Cohort Study From China’s Largest Cardiac
Center
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Bo Xu1, Yongjian Wu1, Yuejin Yang1, Runlin Gao1
1Cardiovascular Institute&Fuwai Hospital, Chinese Academy of Medical Science,
PUMC, Beijing, China
Background: Prior studies implicated that a longer diabetes duration might raise
coronary artery disease (CAD) risks and predict mortality. However, few studies have
addressed its predictive value in patients undergoing coronary revascularization. Thus,
we aimed to evaluate the impact of diabetes duration on long-term clinical outcomes
after primary percutaneous coronary intervention (PCI) or coronary artery bypass
grafting (CABG).
Methods: A total of 820 diabetic patients treated for stable CAD were consecutively
included in this retrospective single-center study. With a median follow-up of 3.5
years, patients’ outcomes were assessed by major adverse cardiac events (MACEs)
and the incidence of nonfatal stroke. MACEs were deﬁned as the need for revascu-
larization, non-fatal myocardial infarction, or cardiovascular death.
Results: At 3-year follow-up, MACE rate was signiﬁcantly higher in PCI- compared
with CABG-treated patients (13.30% vs. 7.02%, p¼0.001). Multivariate Cox
regression analysis revealed that a longer diabetes duration ( 5 years) was an
independent predictor for the incidence of MACEs after PCI (HR¼1.89, 95% CI 1.08-
3.30, p¼0.03), but not CABG (0.21-2.93, p¼0.73). In addition, while CABG was
superior to PCI in patients with diabetes duration  5 years (17.30% vs. 7.21%,
p¼0.003), no difference was observed in those < 5 years (9.36% vs. 6.86%, p¼0.18).
Notably, no differential treatment effect according to the category of SYNTAX score
was found in patients with diabetes duration < or  5 years (p¼0.79 and p¼0.15,
respectively). In contrast to MACEs, nonfatal stroke was more frequent in CABG-
than PCI-treated patients (4.36% vs. 1.13% p¼0.02), with no signiﬁcant interaction
between diabetes duration and treatment strategies on the outcome (p¼0.58).
Conclusions: For stable CAD patients with a longer diabetes duration ( 5 years),
CABG was superior to PCI in that it signiﬁcantly reduced rates of MACEs, despite of
a higher rate of nonfatal stroke. However, for those with a shorter diabetes duration
(< 5 years), PCI was more preferable than CABG, which was independent of the
SYNTAX stratiﬁcation, as it markedly reduced rate of nonfatal stroke without
signiﬁcantly increasing the risk of MACEs.
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Utility of the Residual SYNTAX Score In Patients With Diabetes Mellitus After
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Background: Both diabetes mellitus (DM) and incomplete revascularization (IR) are
associated with a poor prognosis after percutaneous coronary intervention (PCI). We
sought to quantify the extent and impact of IR following PCI using the residual
SYNTAX score (rSS) in patients (pts) with and without DM.
Methods: The rSS was determined by an angiographic core laboratory in 2672 pts
with moderate and high-risk acute coronary syndromes (ACS) undergoing PCI from
the ACUITY trial. Pts were stratiﬁed by rSS tertiles. A rSS¼0 was deﬁned as
complete revascularization (CR). One-year major adverse cardiovascular events
(MACE) according to rSS were examined in DM and non-DM pts.
Results: Overall, 770 (28.8%) pts had DM and 1,902 did not. The mean rSS was
4.96.6 and 4.16.5 in DM and non-DM pts respectively (p¼0.004). CR was ach-
ieved in 35.0% of DM and 42.5% of non-DM pts (p¼0.004). As rSS increased, 1-year
MACE was signiﬁcantly higher in non-DM but not DM pts (Figure). DM pts also had
higher incidence of death (3.0% vs.0.9%; p¼0.01) and MACE at 1-year (22.5% vs.
14.1%; p¼0.001) than non-DM pts, even when CR was achieved.ber 1, 2013 j TCT Abstracts/POSTER/Miscellaneous Coronary Topics
